Promising Improvements in Mild Cognitive Impairment With Investigational NA-831
Researchers from NeuroActiva, Inc. presented results of their randomized, double-blind, placebo-controlled phase 2A clinical trial of NA-831.
AAIC 2018
Tramiprosate Associated With High Response, Favorable Safety in APOE ε4 Homozygotes With Mild Alzheimer’s
Researchers assessed individual patient responses as well as overall response rates to oral tramiprosate and the effect of response on clinical outcomes.
Twice-Daily Oxaloacetate Activates Brain Bioenergetic Metabolism in Alzheimer Disease
The study assessed the pharmacokinetics and pharmacodynamics of 2 doses of oxaloacetate in patients with Alzheimer disease.
Citicoline Plus Memantine Superior to Memantine Alone for Improving Cognition in Alzheimer’s Dementia
Patients in the combination treatment arm experienced a greater increase in MMSE scores between baseline and at 6 months compared with those receiving memantine monotherapy.
New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer’s
Initial data from Study 201, as announced in December 2017, showed BAN2401 did not meet the primary endpoint.
Investigating the Effects of Z-Drugs in Dementia Patients With Sleep Disturbances
Existing data from the the UK Clinical Practice Research Datalink (CPRD) and 3 clinical studies of PwD were used to evaluate the association between Z-drug administration and the incidence of adverse events.
Metformin Associated With Increased Dementia Risk in African Americans With Diabetes
Participants in this study were part of the Indianapolis-Ibadan Dementia Project that took place from 1992 to 2011 and were assessed for dementia every second or third year during follow-up.
Pimavanserin Confers Greater Improvements in Alzheimer Disease Psychosis vs Placebo
Pimavanserin is currently approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Transdermal Buprenorphine Not Well Tolerated in Dementia
The researchers conducted a 13-week study that included 162 individuals with advanced dementia and considerable depression residing in nursing homes in Norway.
Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease
Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.
Next post in AAIC 2018
